Cargando…
Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma that is incurable with existing therapies, and therefore presents a significant unmet clinical need. The ability of this disease to overcome therapy, including those that target the B cell receptor pathway which has a pathogenic...
Autores principales: | Till, Kathleen J., Abdullah, Mariah, Alnassfan, Tahera, Janet, Gallardo Zapata, Marks, Thomas, Coma, Silvia, Weaver, David T., Pachter, Jonathan A., Pettitt, Andrew R., Slupsky, Joseph R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992372/ https://www.ncbi.nlm.nih.gov/pubmed/36882482 http://dx.doi.org/10.1038/s41598-023-30148-3 |
Ejemplares similares
-
Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017) -
The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018) -
Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib
por: Shah, Ankit, et al.
Publicado: (2021) -
Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
por: Flinn, Ian W., et al.
Publicado: (2018) -
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)